ArticleRheumatology and immunology research2020
2020 Chinese Guidelines for the Diagnosis and Treatment of Systemic Lupus Erythematosus.
Article in Rheumatology and immunology research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- The Systemic Lupus Erythematosus Interventional Trials in Mainland China: A Continuous Challenge.Frontiers in immunology · 2022Pooled it
- Anti-CD38 monoclonal antibody CM313 for systemic lupus erythematosus: a randomized, double-blind, placebo-controlled phase Ib/IIa trial.Signal transduction and targeted therapy · 2025Trial
- Trial
- Anti-CD19-engineered exosomes enable B cell-targeted anti-BAFF mRNA delivery to alleviate lupus progression.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Tofacitinib versus BAFF inhibitor in mild to moderate systemic lupus erythematosus: a real-world study based on CSTAR cohort.Clinical rheumatology · 2026Article
- miR-452-5p promotes systemic lupus erythematosus-induced inflammatory responses by downregulating RBL2 and impairing Treg development.Immunologic research · 2026Article
- Efficacy of low dose of rituximab to treat systemic lupus erythematosus.Frontiers in immunology · 2026Article
- Changes in attitudes toward systemic lupus erythematosus and associated factors: a retrospective cross-sectional study from China.Frontiers in immunology · 2026Observational
- Anti-CENP-B polarity divides SLE: divergent clinical-immune phenotypes and distinct treatment responses.Frontiers in immunology · 2026Article
- Verification of biological markers of subacute cutaneous lupus erythematosus via TMT labelling proteomics combined with transcriptome data.Annals of medicine · 2025Article
- Association between inflammatory cytokines and carotid plaque in young and middle-aged adults.Biochemistry and biophysics reports · 2025Article
- Cre-driven tdTomato expression unexpectedly confers resistance to peripheral but not central lupus in dLckCre mice.Journal of translational autoimmunity · 2025Article
- Efficacy of tacrolimus and other immunosuppressants in the treatment of systemic lupus erythematosus: A systematic review and meta-analysis.Biomedical reports · 2025Article
- How will we treat systemic lupus erythematosus in the next 5 years?Rheumatology and immunology research · 2025Article
- Article
- Management of newly diagnosed lupus nephritis in China: An implementation study based on the 2023 EULAR recommendations.Clinical rheumatology · 2025Article
- Sirolimus versus mycophenolate mofetil for the treatment of lupus nephritis: Results from a real-world CSTAR cohort study.Rheumatology and immunology research · 2025Article
- Fatigue and associated factors among patients with systemic lupus erythematosus in China: a cross-sectional study.Frontiers in medicine · 2025Article
- Effect of tacrolimus with mycophenolate mofetil or cyclophosphamide on the renal response in systemic lupus erythematosus patients.BMC rheumatology · 2024Article
- Risk factors of disease activity and renal damage in patients with systemic lupus erythematosus.International urology and nephrology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 13 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease that represents a prodigious challenge of diagnosis and treatment. In 2019, under the leadership of the Chinese Rheumatology Association, a multidisciplinary guideline development group was established to develop an evidence-based diagnosis and treatment guideline for patients with SLE in PR China. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to evaluate the quality of evidence and the strength of recommendations. The guideline was reported following the Reporting Items for Practice Guidelines in Healthcare (RIGHT) checklist. In this guideline, we provided recommendations for SLE classification criteria, disease activity monitoring and assessment, medication administration and considerations for SLE patients with organs and systems involved, and management of special populations such as SLE patients in the setting of pregnancy. This guideline serves as an evidence-based tool for Chinese clinicians to diagnose and treat patients with SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.